🔎 Trials Near Me

Home › Chronic Lymphocytic Leukemia › Ohio › Columbus

Chronic Lymphocytic Leukemia clinical trials in Columbus, OH

28 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in and around Columbus (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

RecruitingPhase 3
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Columbus Oncology and Hematology Associates Inc, Columbus
  • Riverside Methodist Hospital, Columbus
  • and 8 more
Ages 65 and older · All sexes · Updated Oct 2, 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RecruitingObservational studyHealthy volunteers welcome
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Mount Carmel East Hospital, Columbus
  • The Mark H Zangmeister Center, Columbus
  • and 8 more
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

RecruitingPhase 3
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04269902

Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia

RecruitingPhase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 75 and older · All sexes · Updated Sep 28, 2026 · NCT07685717

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

RecruitingPhase 2
  • The Ohio State University, Columbus
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07221500

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

RecruitingPhase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07061951

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

RecruitingPhase 1/2
  • Research Site, Columbus
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06564038

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

RecruitingPhase 1
  • The James Cancer Hospital and Solove Research Institute, Columbus
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05091424

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

RecruitingPhase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT07734038

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

RecruitingPhase 3
  • OSU Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07342478

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

RecruitingPhase 1/2
  • The Ohio State University Wexner Medical Center, Columbus
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

RecruitingPhase 1
  • The Ohio State University, Columbus
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06708897

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

RecruitingPhase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT07271667

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

RecruitingPhase 1
  • Nationwide Children's Hospital, Columbus
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 2 and older · All sexes · Updated May 29, 2026 · NCT05418088

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

RecruitingPhase 1
  • The Ohio State University, Columbus
Ages 13 and older · All sexes · Updated May 5, 2026 · NCT04771572

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

RecruitingPhase 4
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

RecruitingPhase 4
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876649

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

RecruitingPhase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Feb 19, 2026 · NCT06466122

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

RecruitingPhase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Feb 19, 2026 · NCT05336812

Study of SGR-1505 in Mature B-Cell Neoplasms

RecruitingPhase 1
  • The Ohio State University - The James Cancer Hospital, Columbus
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

RecruitingPhase 2
  • The Ohio State University /ID# 230439, Columbus
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT04895436

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

RecruitingPhase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT05417165

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

RecruitingPhase 2
  • The Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT06043674

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

RecruitingPhase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Dec 16, 2025 · NCT06757647

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

RecruitingPhase 1
  • The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
Ages 18 and older · All sexes · Updated Oct 2, 2025 · NCT05780034

HPC Offered for PRESERVE Expansion

RecruitingObservational study
  • The Ohio State University Medical Center, Columbus
Ages 12 to 80 · All sexes · Updated Aug 28, 2025 · NCT07145411

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

RecruitingPhase 1/2
  • The Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Aug 4, 2022 · NCT04502394

Chronic Lymphocytic Leukemia trials in other cities

Other studies in Columbus

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.